packageRuxolitinib

ruxolitinib

Extends from Pharmacolibrary.Interfaces.PartialSubstance (Identity and physicochemical constants of one drug (Drugs.Substances)).

Information

Ruxolitinib, a JAK inhibitor, is used for myeloproliferative disorders such as myelofibrosis and polycythemia vera, for graft-versus-host disease, and as a skin preparation for vitiligo. It is approved and authorised in the European Union, with additional investigational uses.

Summary written by glm-5.3-flash from Wikidata Q7383611 and the WHO ATC classification and the EMA medicines list; not checked by a person.

name:ruxolitinib
ATC codes:D11AH09, L01EJ01
DrugBank:DB08877
PubChem CID:25126798
ChEBI:66919
Wikidata:Q7383611
formula:C17H18N6
molar mass:306.373 g/mol (PubChem CID 25126798)
logP:2.1 (Drugs.Common 25.09, not verified)

Parameters

TypeNameDefaultDescription
Stringname (from PartialSubstance)""INN / common name
String[:]atcCodes (from PartialSubstance)fill("", 0)all WHO ATC codes of the drug
StringdrugbankId (from PartialSubstance)""e.g. DB00758
StringpubchemCid (from PartialSubstance)""PubChem compound id
StringchebiId (from PartialSubstance)""ChEBI id (number)
StringwikidataId (from PartialSubstance)""e.g. Q410238
Stringformula (from PartialSubstance)""molecular formula
Modelica.Units.SI.MolarMassM (from PartialSubstance)0molar mass; 0 = unknown
ReallogP (from PartialSubstance)Modelica.Constants.infoctanol-water partition coefficient (log10); inf = unknown